GST Council To Discuss Input Tax Credit Relief for Pharmaceutical Samples

GST Council May Offer Relief to Pharma Sector on ITC for Free Drug Samples

The Goods and Services Tax (GST) Council is expected to deliberate a key issue that has long troubled India’s pharmaceutical sector: whether manufacturers can claim Input Tax Credit (ITC) on free drug samples distributed to healthcare professionals. The clarification, if approved, could ease a long-standing compliance bottleneck and unlock significant working capital for the industry.

What’s the Core Issue?

At present, Section 17(5)(h) of the CGST Act bars businesses from claiming ITC on goods "disposed of by way of gift or free samples." This interpretation was reaffirmed through CBIC Circular No. 92/11/2019-GST, which requires reversal of credit on such free distributions. The reasoning is that goods provided without consideration do not qualify as "supply," and thus fall outside the ITC framework—unless they meet exceptions outlined in Schedule I (like inter-branch transactions).

Why Pharma Is Seeking a Carve-Out

Pharmaceutical companies argue that free samples are not consumer giveaways but serve a professional and scientific purpose. These samples are distributed only to licensed doctors and hospitals, often as part of regulatory engagement or clinical feedback processes.

A senior pharma executive told CNBC-TV18,

"We’re not handing out shampoo sachets. Doctors use these samples to test efficacy, inform prescriptions, and support R&D validation. Blocking ITC here makes no business or clinical sense."

For large firms, such samples account for 1–2% of production costs, translating to crores in blocked credit. In a high-volume, price-sensitive sector, this adds pressure to already thin margins.

What Might the GST Council Consider?

At its upcoming meeting, the Council may explore issuing a clarificatory circular or notification allowing ITC for certain types of pharma samples—while also introducing clear conditions to prevent misuse. Key proposals under discussion include:

• Limiting eligibility to prescription-only drugs (e.g., Schedule H or X medications)
• Capping the monetary value of samples eligible for ITC
• Requiring auditable distribution mechanisms, such as doctor licensing records and traceable sample logs

Such safeguards aim to ensure that any ITC relief is used for legitimate professional outreach, not disguised marketing.

Why the Reluctance from Authorities?

Officials remain cautious. A broad green light on ITC for free goods could open the floodgates to abuse across other sectors—where freebies are routinely used for brand promotions. Hence, regulators are considering a narrowly-defined benefit limited to the highly regulated pharma ecosystem, where documentation and audit trails are more robust.

Industry Reaction: Cautious Optimism

For now, pharma companies are watching the Council’s move closely. Industry analysts say any clarification in favour of ITC could:

• Release working capital stuck due to reversed or unclaimed credits
• Reduce litigation and back-and-forth with tax officers
• Promote regulatory certainty, especially for companies scaling up their sampling models or launching new molecules

What Happens Next?

The Council is expected to take up the matter at its next meeting later this month. If the clarification goes through, it could mark a precedent-setting policy shift for sectors where “free goods” serve functional, non-promotional purposes.

This move could:

• Unlock ITC in a space previously marked by ambiguity
• Provide direct cash flow relief to manufacturers
• Create a model framework for sector-specific exemptions under GST

Quick FAQs: Pharma Free Samples and GST ITC

Q1. Why is ITC on free samples disallowed today? Section 17(5)(h) of the CGST Act treats free samples as goods given without consideration, making them ineligible for ITC unless covered under Schedule I.

Q2. Why should pharma samples be treated differently? They’re not consumer promotions. Samples are provided to doctors under regulated, documented protocols to test and evaluate new drugs.

Q3. What safeguards are being discussed? Likely measures include caps on value, restricting relief to prescription-only drugs, and linking ITC to traceable doctor-distribution data.

Q4. What’s the potential financial impact? For larger firms, up to 2% of production costs currently go into such samples. Unlocking ITC here could significantly ease margin pressure.

Final Word: For pharma manufacturers, this could be a turning point. If you’re in the sector—or advising those who are—it’s time to prepare documentation and review current sampling practices. The GST landscape may be about to shift.